Home Blog Page 469

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

– Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5 billion acquisition by Merck and at Viridian Therapeutics –

BOSTON, March 19, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc. (“Bambusa”), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the appointment of Mr. Todd James as Executive Vice President, Chief Financial Officer (CFO). Mr. James’s appointment strengthens Bambusa’s financial leadership, stakeholder engagement, and expands its executive team as the Company advances its clinical pipeline and executes its long-term growth strategy.

“We are thrilled to welcome Todd to Bambusa as our Chief Financial Officer,” said Dr. Shanshan Xu, Founder and Chief Executive Officer of Bambusa Therapeutics. “As we continue to scale our company and expand our executive team, Todd brings a proven track record of capital markets execution and strategic leadership. Having had the opportunity to engage with him in my time as a research analyst—and most recently benefiting from his collaboration as a senior advisor to Bambusa—I have seen firsthand his ability to support long-term value creation through shaping corporate strategy, educating and engaging key external stakeholders, and building high-performing teams. His addition comes at a pivotal time as we advance our innovative bispecific antibody pipeline in I&I toward our 2+2 vision—advancing BBT001 and BBT002 into pivotal studies and progressing BBT003 and BBT004 into proof-of-concept studies for 2028.”

Mr. James brings more than 20 years of senior leadership experience in the biopharmaceutical industry, with deep expertise in capital markets, investor relations, and corporate strategy. He most recently served as Senior Vice President of Corporate Affairs and Investor Relations and was a member of the executive leadership team at two publicly traded biotechnology companies: Acceleron Pharma, prior to its $11.5 billion acquisition by Merck, and Viridian Therapeutics.

During his tenure at Acceleron from 2015 to 2021, Mr. James established and led the company’s in-house investor relations, corporate affairs, and internal and external communications functions. He was a key contributor to Acceleron’s strategic financing activities, helping execute four successful financings that collectively raised more than $1 billion. From 2019 through 2021, he was named to Institutional Investor magazine’s All-America Executive Team as Best Investor Relations Professional in Biotechnology.

Earlier in his career, Mr. James spent nine years at Trout Group and Trout Capital, where he advised biopharmaceutical companies on investor relations, capital raising, and corporate strategy. He began his career on Wall Street within the Biotechnology Capital Markets Intelligence team at Thomson Financial. Mr. James holds a Bachelor of Arts degree in Economics, with a concentration in Finance from Moravian University.

“Shanshan and the Bambusa team have built a differentiated biopharmaceutical company focused on the I&I space, anchored by a platform of bispecific antibodies designed to engage complementary, validated therapeutic targets,” said Mr. James. “I am excited to partner with the team to further strengthen Bambusa’s financial strategy and external engagement as we advance the Company’s mission to deliver transformative medicines across I&I disease areas while creating meaningful long-term value for patients and investors.”

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio designed to transform care across a wide spectrum of chronic diseases. Powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery, Bambusa’s vision is to deliver transformative medicines for patients across every stage of life — setting a new pace for the next era of I&I therapeutics.

  • BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase Ib proof-of-concept development for atopic dermatitis and other type 2 inflammatory skin diseases.
  • BBT002 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with platform-in-a-molecule potential. It is currently in Phase Ib proof-of-concept development for type 2 inflammatory disorders including COPD, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, and food allergy.
  • BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology, respectively.

 

Bybit Introduces Yield-Bearing Gold Product Offering APR on Tokenized Gold

DUBAI, UAE, March 19, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has launched XAUT Earn, a product that enables users to earn interest on tokenized gold holdings, a feature that remains uncommon across both traditional and digital gold markets.

The XAUT Earn product allows users to generate yield on Tether Gold (XAUT), a digital asset backed by physical gold. The launch introduces an alternative model for gold ownership by combining price exposure with income generation, in contrast to conventional gold products that typically do not offer yield.

As part of the launch, Bybit is offering two XAUT savings products: flexible staking and fixed-term savings options, both offering APR.

Gold has historically served as a safe-haven asset during periods of economic uncertainty, but it has not traditionally generated income for holders. Physical gold, exchange-traded funds, and other tokenized gold products such as PAXG typically do not natively offer yield. XAUT Earn introduces a structure that allows holders to retain gold exposure while earning returns.

Interest-bearing gold products remain limited across the broader market, where yield opportunities are predominantly concentrated in stablecoins. The introduction of XAUT Earn expands the range of yield-generating instruments tied to real-world assets within the digital asset ecosystem.

The product reflects growing demand for assets that combine capital preservation with yield generation. This approach broadens the utility of gold for both traditional investors and digital asset users. The offering is designed to appeal to a wide range of participants, including traditional gold holders seeking additional utility, crypto users seeking diversification beyond stablecoin-based yield products, and risk-averse investors interested in combining defensive assets with income-generating strategies.

The launch forms part of Bybit’s ongoing efforts to expand its product suite and bridge traditional and digital finance through asset-backed yield solutions.

#Bybit / #CryptoArk

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

 

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

NANTONG, China, March 19, 2026 /PRNewswire/ — Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its Investigational New Drug (IND) application to initiate a Phase II clinical trial of RAG-01 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

This significant milestone makes RAG-01 the second saRNA therapeutic to receive IND approval in China, both of which were developed by Ractigen. This approval not only solidifies Ractigen’s global leadership in saRNA technology but also serves as a critical clinical validator for the company’s broader RNA activation (RNAa) platform and its LiCOTM delivery technology.

RAG-01 is a novel saRNA therapeutic designed to upregulate p21, a key regulator of cell cycle arrest and cellular senescence, to inhibit the abnormal proliferation of bladder cancer cells. This innovative saRNA therapeutic aims to treat NMIBC by increasing p21 mRNA and protein levels.

The progression of RAG-01 into Phase II clinical development follows highly encouraging Phase I data from Australia, which demonstrated clear target engagement (p21 protein upregulation), a favorable safety profile, and promising complete response (CR) signals.

“We are very pleased to receive IND approval from the China NMPA CDE for the Phase II trial of RAG-01,” said Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics. “This approval is an important validation of both the RAG-01 program and the broader potential of saRNA therapeutics. RAG-01 reflects our innovation strategy of activating endogenous disease-relevant genes that have long been considered difficult to drug. We believe this differentiated mechanism, together with local bladder delivery, may offer a meaningful new treatment option for patients with NMIBC. We look forward to working closely with investigators and regulatory authorities to advance this program.”

The Phase II study is a randomized, controlled, multi-center trial designed to evaluate the efficacy and safety of RAG-01 as monotherapy and in combination with chemotherapy in patients with intermediate- and high-risk NMIBC. The China study builds on encouraging preliminary data from the ongoing Phase I clinical trial in Australia, where RAG-01 has demonstrated favorable safety, clear target engagement, and anti-tumor activity.

About RAG-01

RAG-01 is a pioneering saRNA therapeutic candidate designed to activate the tumor suppressor gene p21 via RNA activation (RNAa). The product is administered through intravesical instillation using Ractigen’s proprietary LiCO™ delivery technology. In the Phase I clinical trial conducted in Australia, RAG-01 has shown encouraging  preliminary safety, target engagement, and efficacy data. In 2024, RAG-01 received IND clearance from the U.S. Food and Drug Administration (FDA) and was granted Fast Track designation.

About NMIBC

Non-muscle invasive bladder cancer (NMIBC) is a common malignancy confined to the lining of the bladder. The standard first-line treatment is transurethral resection of the bladder tumor (TURBT) followed by intravesical BCG or chemotherapy. However, a significant proportion of patients experience treatment failure or multiple recurrences, highlighting the need for new and effective treatment options.

About RNAa

RNA activation is a clinically validated platform technology developed by Dr. Long-Cheng Li and his team. It utilizes saRNAs to target gene regulatory domains, activating gene expression and restoring therapeutic protein levels. This innovative technology holds vast potential for developing therapeutic drugs across various diseases, particularly where traditional methods fall short.

About Ractigen Therapeutics

Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com.

Relativity Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

CHICAGO, March 19, 2026 /PRNewswire/ — Relativity, a legal data intelligence company, today announced that it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed initial public offering remains subject to the completion of the SEC review process, as well as market and other conditions.

Relativity
Relativity

This press release is being issued pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”). This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Crayola Partners with Luxor to Expand Business in India: Encouraging Hands-on Creativity and Imaginative Play to Create Joy

EASTON, Pa., March 19, 2026 /PRNewswire/ — Crayola, a global leader in art and stationery products, is thrilled to announce a strategic long-term partnership with Luxor Writing Instruments Pvt. Ltd., the leading stationery and writing instrument manufacturer in India. This collaboration marks a significant milestone for both companies as they join to bring Crayola, America’s number one brand, to millions of Indian families.

Through this partnership, Crayola and Luxor aim to share the importance of creativity and self-expression as essential life skills. Crayola and Luxor want to inspire a new generation of children to explore their imagination, build confidence, and express their unique ideas through hands-on artistic experiences. Drawing on more than 120 years as a brand trusted by parents, respected by teachers, and loved by children, Crayola will bring joyful creative moments to families across India with Luxor’s scale and reach in one of the world’s fast-growing and youngest consumer markets.

Luxor will manufacture and distribute Crayola products, making them accessible to India’s 436 million children. The products will be co-branded Crayola by Luxor, symbolizing the collaborative nature of this partnership and a shared commitment to quality, safety, and creativity.

“We are excited about our partnership with Luxor,” says Ben Thomas, Crayola Chief Commercial Officer and Executive Vice President of Marketing. “Their manufacturing and distribution expertise and knowledge of the market in India aligns well with our growth objectives. Luxor shares our commitment to brand excellence – engaging parents, teachers, and children in imaginative play to create joy.”

“At Crayola, we’ve always believed creativity helps children build confidence, curiosity, and innovative thinking, which are essential skills for the future,” says Pete Ruggiero, Crayola President & Chief Executive Officer. “India’s education landscape is going through an important transformation. With the National Education Policy 2020, there is a clear shift toward experiential learning and problem-solving. When you combine that shift with the scale of India’s education system, 260 million students across more than 1.5 million schools, the opportunity to nurture creativity becomes incredibly powerful.”

By making artistic tools more accessible, Crayola and Luxor aim to inspire a lifelong love of creativity and help families and teachers see self-expression as a meaningful and valuable part of everyday life. As a globally recognized brand, Crayola is known for its rigorous safety standards, high-quality manufacturing, and innovative products that inspire imagination and creative confidence. Crayola is celebrating a record year of innovation, with 47 U.S. patents filed over the past 18 months, as the brand continues to reimagine how creativity comes to life. Crayola and Luxor are committed to upholding the highest standards of safety and quality while introducing innovative new products that reflect their shared dedication to providing children and families with trusted tools for creative expression.

For more information about this partnership and upcoming product launches, please visit https://www.luxorpen.com/ and www.crayola.com.

Karen Kelly, Crayola
484-695-1993
kkelly2@crayola.com 

Hanskin Lands in 1,400 ULTA Beauty Stores, Bringing Glass Skin Hydration to the U.S.

The Global K-Beauty Bestseller Brings Deep Hydration, Glass Skin Glow, and Next-Gen PDRN Skincare to the U.S.

CHICAGO and NEW YORK and LOS ANGELES, March 19, 2026 /PRNewswire/ — K-Beauty skincare brand Hanskin by Celltrion Skincure is expanding its North American presence with a major retail milestone, launching in approximately 1,400 stores of ULTA Beauty across the United States.

Credit: @alexabeckford
Credit: @alexabeckford

The nationwide rollout marks a pivotal moment for Hanskin as the brand moves beyond its strong online presence—particularly on Amazon—and into large-scale offline retail distribution. By entering ULTA Beauty’s extensive store network, Hanskin aims to bring its signature glass skin hydration philosophy to millions of U.S. beauty consumers.

The product debuting across ULTA Beauty stores is Hanskin’s global bestseller, Hyaluron Skin Essence—a lightweight, deeply hydrating formula designed to deliver the coveted glass skin glow. Powered by high-purity hyaluronic acid, the essence provides intense hydration while maintaining a fast-absorbing, layerable texture ideal for modern skincare routines.

Already a consistent top-selling product across global markets—including North America, Europe, and the Middle East—the essence has gained popularity for its ability to deliver plump, radiant skin without heaviness. With U.S. consumers increasingly seeking hydration-focused skincare and glass skin-inspired glow, the formula is positioned as a daily essential for achieving healthy, luminous skin.

Hanskin is also expanding beyond hydration into next-generation biotech K-Beauty skincare. The brand recently introduced the Ara Lotus PDRN Hyaluron Glow Serum, an advanced glow serum powered by Hanskin’s proprietary lotus-derived PDRN technology.

Unlike traditional salmon PDRN ingredients, Hanskin’s plant-based lotus PDRN is engineered to deliver faster and deeper skin absorption, helping enhance elasticity, radiance, and skin vitality. The formula delivers a combination of hydration, firming care, and glow-enhancing benefits, representing a new evolution of PDRN-powered skincare innovation.

The serum also incorporates biotechnology-driven ingredient purification and stabilization processes developed by Celltrion Skincure, optimizing the molecular design and delivery efficiency of high-purity PDRN. Featuring 200,000 PPM of concentrated PDRN, the formula maximizes skin absorption and efficacy. This innovation allows Hanskin to expand beyond hydration-focused skincare into biotech-driven K-Beauty solutions centered on glow, regeneration, and skin vitality.

With the ULTA Beauty launch of Hyaluron Skin Essence, Hanskin plans to gradually expand its U.S. lineup with advanced skincare innovations including PDRN and retinol-based formulations. By combining deep hydration with skin-firming and glow-enhancing technologies, the brand aims to position itself as a leader in hydration-plus-glow K-Beauty skincare.

Through increased visibility across major retail locations in cities such as Chicago, New York, and Los Angeles, Hanskin aims to strengthen its presence in the U.S. beauty market and establish itself as a rising K-Beauty brand known for delivering healthy, radiant skin.

About Hanskin

Hanskin is an iconic K-Beauty skincare brand where Celltrion’s cutting-edge bioscience meets global beauty innovation. Combining advanced biotechnology with trend-driven formulations, Hanskin creates high-performance skincare designed to deliver deep hydration, luminous glow, and naturally flawless, glass-like skin.

MDJM LTD Announces Receipt of Nasdaq Suspension Determination and Plans to Request a Hearing before an Independent Nasdaq Hearings Panel

LETHAM, Scotland, March 19, 2026 /PRNewswire/ — MDJM LTD (Nasdaq: UOKA) (the “Company”), an integrated global culture innovation company, today announced that the Company received a staff determination letter (the “Letter”), on March 13, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, as the Company’s securities had a closing bid price of $0.10 or less for 10 consecutive business days, its securities would be suspended effective with the open of trading on March 20, 2026. Because the Company effected a 1 for 25 reverse stock split on May 20, 2025,the Company is also subject to the provisions set forth in Nasdaq Listing Rule 5810(c)(3)(A)(iii) and Rule 5810(c)(3)(A)(iv). In addition, following the Nasdaq Listing Qualifications Panel’s decision dated November 19, 2025, the Company is subject to a Discretionary Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(A) for a period of one year.

The Company intends to timely request a hearing before an independent Hearings Panel (the “Panel”). Notwithstanding, given that the Company traded below $0.10 for 10 consecutive business days, the hearing request will not stay the suspension of the Company’s securities. During the pendency of the hearing, the Company expects that its securities will be eligible to be traded on the OTC Markets under the same ticker symbol “UOKA.” There can be no assurance that the Panel will grant the Company’s request for continued listing or otherwise provide relief from the suspension determination, and the ultimate outcome of the hearing process remains uncertain.

The Company is currently considering all options available to regain compliance with Nasdaq’s listing requirements and return to good standing on Nasdaq, including a reverse stock split, which became effective on March 16, 2026, and will provide its shareholders with any material updates when they are available.

About MDJM LTD

MDJM LTD is a global culture innovation company focused on cultural IP development, animation production, international licensing, and cultural venue operations. The Company has been expanding its operations in the UK, where it is developing projects such as Fernie Castle in Scotland and the Robin Hill Property in England. These properties are being remodeled into multi-functional cultural venues that will feature fine dining, hospitality services, art exhibitions, and cultural exchange events. As part of its broader strategy, the Company is collaborating with select European animation studios to develop animated short films that blend Eastern themes with Western artistry. The Company aims to integrate Eastern philosophy with international artistic practices, creating a global cultural ecosystem built on storytelling and immersive experience. This initiative reflects the Company’s commitment to furthering its global market expansion and enhancing its cultural business footprint. For more information regarding the Company, please visit https://www.ir-uoka.com/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission.

Investor Contact

Sherry Zheng
WAVECREST GROUP INC.
Phone: +1 718-213-7386
Email: sherry@wavecrestipo.com 

YY Group Announces Effective Date of Reverse Stock Split

SINGAPORE, March 19, 2026 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced that its Board of Directors has resolved to effect a 50-for-1 reverse stock split of the Company’s Class A ordinary shares. YY Group’s Class A ordinary shares will begin trading on an adjusted basis giving effect to the reverse stock split on March 23, 2026, under the existing ticker symbol “YYGH.” The new CUSIP number of the Company’s ordinary shares will be G9888Q111.

When the reverse stock split becomes effective, every Fifty (50) of the Company’s issued and outstanding Class A ordinary shares will be combined into one issued and outstanding Class A ordinary share, without any change to the no-par value per share. This will reduce the number of outstanding Class A ordinary shares from approximately 207.4 million shares to approximately 4.1 million shares. Immediately following the effective time of the reverse stock split, the Company’s Class A ordinary shares will have the same voting rights and will be identical in all other respects to the Class A ordinary shares prior to the effectiveness of the reverse stock split.

No fractional shares will be issued in connection with the reverse stock split. Shareholders who would otherwise receive a fraction of a Class A ordinary share of the Company will receive one full share.

The reverse stock split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its Nasdaq listing.

About YY Group Holding Limited

YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, technology-enabled platform providing flexible, scalable workforce solutions and integrated facility management (IFM) services across Asia and beyond. The Group operates through two core verticals: on-demand staffing and IFM, delivering agile, reliable support to industries such as hospitality, logistics, retail, and healthcare.

Leveraging proprietary digital platforms and IoT-driven systems, YY Group enables clients to meet fluctuating labor demands and maintain high-performance environments. In addition to its core operations in Singapore and Malaysia, the Group maintains a growing presence in Asia, Europe, Africa, Oceania and the Middle East.

Listed on the Nasdaq Capital Market, YY Group is committed to service excellence, operational innovation, and long-term value creation for clients and shareholders.

For more information on the Company, please visit https://yygroupholding.com/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about YY Group Holding Limited’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and YY Group Holding Limited undertakes no duty to update such information, except as required under applicable law.

Investor Contact
Jason Phua Zhi Yong, Chief Financial Officer
YY Group
enquiries@yygroupholding.com